Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms SJ000986049 |
Target |
Action degraders |
Mechanism JAK2 degraders(Tyrosine-protein kinase JAK2 degraders) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC42H48N10O9 |
InChIKeyBYIWLZCCIGPLHU-UHFFFAOYSA-N |
CAS Registry2595365-55-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 10 May 2021 | |
Rheumatoid Arthritis | Preclinical | United States | 10 May 2021 |